{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:03:16Z","timestamp":1775098996241,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Purpose: Radiotherapy is integral in the management of hematological malignancies (HM). Standard radiotherapy dose fractionation regimens range between 20 and 50 Gy in 10\u201325 fractions over 2\u20135 weeks. This study presents the outcomes of patients with HM treated with hypofractionation radiotherapy (HFRT) during the COVID-19 pandemic. Methods: Patients (n = 36) were treated with HFRT between January 2020 and September 2022. The outcomes measured were the overall response rate (ORR), freedom from local progression (FFLP), and overall survival (OS). Results: The median follow-up was 13.2 months. Thirty-three patients (92%) had non-Hodgkin (NHL) or Hodgkin lymphoma (HL). Eighteen patients (50%) had aggressive and nine (25%) had indolent NHL. Nineteen patients (53%) presented with stage I\/II and fifteen (42%) with stage III\/IV disease. Twenty-five (69.4%) and eleven (30%) received consolidative and definitive RT, respectively. Twenty patients (56%) received treatment to the neck and\/or thorax and nine (25%) to the abdomen or pelvis. The total dose ranged from 18 to 42.5 Gy in 6\u201317 fractions\/2.67\u20135 Gy per fraction. The median dose in 2 Gy fractions for an alpha\/beta (\u03b1\/\u03b2) ratio of 10 amounted to 39 Gy (SD \u00b1 13.86) and 43.6 Gy (SD \u00b1 12) for an \u03b1\/\u03b2 of 3. The most commonly used fractionation scheme was 39 Gy in 13 fractions. ORR was 94.4% for the entire cohort, and 100, 94.4, and 83.3% for indolent NHL, aggressive NHL, and HL patients. The two-year FFLP was 76% (95% CI: 34\u201393%) for the entire cohort and 100, 87 (95% CI: 56.4\u201396.5%), and 42% (95% CI: 1.1\u201384.3%) for the indolent NHL, aggressive NHL, and HL patients. Two-year OS for the entire cohort was 80% (95% CI: 59.9\u201390.5%) and 100, 66.1 (95% CI: 36.4\u201384.4%), and 100% for the indolent NHL, aggressive NHL, and HL patients. Only one patient presented with grade two pulmonary toxicity. Conclusions: HFRT in HM provides excellent local control to be validated in a larger prospective study.<\/jats:p>","DOI":"10.3390\/curroncol31010025","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T09:39:57Z","timestamp":1704879597000},"page":"383-393","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hypofractionated Radiotherapy for Hematologic Malignancies during the COVID-19 Pandemic and Beyond"],"prefix":"10.3390","volume":"31","author":[{"given":"Febin","family":"Antony","sequence":"first","affiliation":[{"name":"Section of Radiation Oncology, Department of Radiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arbind","family":"Dubey","sequence":"additional","affiliation":[{"name":"Section of Radiation Oncology, Department of Radiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Skrabek","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology\/Hematology, Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3A TR9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lung Fung","family":"Tsang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bohdan","family":"Bybel","sequence":"additional","affiliation":[{"name":"Section of Nuclear Medicine, Department of Radiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naseer","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Section of Radiation Oncology, Department of Radiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada"},{"name":"CancerCare Manitoba Research Institute, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijrobp.2019.10.029","article-title":"Making Every Single Gray Count: Involved Site Radiation Therapy Delineation Guidelines for Hematological Malignancies","volume":"106","author":"Dabaja","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: Field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","article-title":"Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group","volume":"101","author":"Tsang","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijrobp.2018.05.045","article-title":"Use of radiation in extramedullary leukemia\/chloroma: Guidelines from the International Lymphoma Radiation Oncology Group","volume":"102","author":"Bakst","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5306\/wjco.v10.i1.14","article-title":"Stereotactic body radiation therapy for non-small cell lung cancer: A review","volume":"10","author":"Prezzano","year":"2019","journal-title":"World J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12094-015-1361-4","article-title":"Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients","volume":"18","author":"Ceniceros","year":"2016","journal-title":"Clin. Transl. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8170428","DOI":"10.1155\/2019\/8170428","article-title":"The financial impact of hypofractionated radiation for localized prostate cancer in the United States","volume":"2019","author":"Moore","year":"2019","journal-title":"J. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1440-1584.2011.01232.x","article-title":"Travelling all over the countryside: Travel-related burden and financial difficulties reported by cancer patients in New South Wales and Victoria","volume":"19","author":"Zucca","year":"2011","journal-title":"Aust. J. Rural Health"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijrobp.2020.06.054","article-title":"Radiation fractionation schedules published during the COVID-19 pandemic: A systematic review of the quality of evidence and recommendations for future development","volume":"108","author":"Thomson","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_13","first-page":"55","article-title":"COVID-19: Global radiation oncology\u2019s targeted response for pandemic preparedness","volume":"22","author":"Simcock","year":"2020","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood.2020006028","article-title":"ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic","volume":"135","author":"Yahalom","year":"2020","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: A review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"Oei","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","article-title":"Common toxicity criteria: Version 2.0. an improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy","volume":"47","author":"Trotti","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","first-page":"27","article-title":"The roles of radiotherapy and immunotherapy for the treatment of lymphoma","volume":"5","author":"Kimball","year":"2013","journal-title":"Mol. Cell. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: An overview of international lymphoma radiation oncology group guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ahmed, N., Owen, T.E., Rubinger, M., Williams, G., Nugent, Z., Ahmed, S., and Cooke, A. (2013). Early stage WHO grade I and II follicular lymphoma treated with radiation therapy alone. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0065156"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/ajh.25856","article-title":"Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management","volume":"95","author":"Ansell","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11899-019-00499-8","article-title":"Solitary plasmacytoma: A review of diagnosis and management","volume":"14","author":"Pham","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1259\/0007-1285-62-740-679","article-title":"The linear-quadratic formula and progress in fractionated radiotherapy","volume":"62","author":"Fowler","year":"1989","journal-title":"Br. J. Radiol."},{"key":"ref_26","unstructured":"Brenner, D.J. (2008). Seminars in Radiation Oncology, WB Saunders."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2307\/3577305","article-title":"The relationship of DNA and chromosome damage to survival of synchronized X-irradiated L5178Y cells: II. Repair","volume":"115","author":"Wlodek","year":"1988","journal-title":"Radiat. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0027-5107(98)00107-9","article-title":"A brief survey of aberration origin theories","volume":"404","author":"Savage","year":"1998","journal-title":"Mutat. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0167-8140(84)80074-2","article-title":"The radioresponsiveness of human tumours and the initial slope of the cell survival curve","volume":"2","author":"Deacon","year":"1984","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1088\/0031-9155\/51\/11\/009","article-title":"Fitting the linear-quadratic model to detailed data sets for different dose ranges","volume":"51","author":"Garcia","year":"2006","journal-title":"Phys. Med. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/0360-3016(82)90459-X","article-title":"Dose fractionation, dose rate and iso-effect relationships for normal tissue responses","volume":"8","author":"Barendsen","year":"1982","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_32","first-page":"2817","article-title":"Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines","volume":"58","author":"Aldridge","year":"1998","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101016","DOI":"10.1016\/j.adro.2022.101016","article-title":"Radiation Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: What Is the Right Regimen for Palliation?","volume":"7","author":"Wright","year":"2022","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Takahashi, I., Kashiwado, K., Adachi, Y., Imano, N., Takeuchi, Y., Nishibuchi, I., Murakami, Y., Kimura, T., and Nagata, Y. (2019). The Efficacy of Hypofractionated Radiotherapy for Local Control in Aggressive non-Hodgkin Lymphoma. Int. J. Radiat. Oncol. Biol. Phys., 105.","DOI":"10.1016\/j.ijrobp.2019.06.1444"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.21873\/anticanres.16549","article-title":"Outcome of Hypofractionated Radiotherapy for Localized Gastric Mucosa-associated Lymphoid Tissue Lymphoma","volume":"43","author":"Ochi","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"109580","DOI":"10.1016\/j.radonc.2023.109580","article-title":"Potential synergy between radiotherapy and CAR T-cells-a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy","volume":"183","author":"Fan","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_37","unstructured":"(2022, June 01). CCMB Practice Guide Lines. Available online: https:\/\/www.cancercare.mb.ca\/For-Health-Professionals\/treatment-guidelines-regimen-reference-orders."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"20219005","DOI":"10.1259\/bjr.20219005","article-title":"Lymphoma: Advances in imaging and radiotherapy\u2013introductory editorial","volume":"94","author":"Illidge","year":"2021","journal-title":"Br. J. Radiol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/1\/25\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:43:30Z","timestamp":1760103810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/1\/25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["curroncol31010025"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31010025","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]}}}